Biosceptre has established a strong pipeline for oncology immunotherapy against nfP2X7 spanning a range of therapeutic modalities.

Our data has shown that drugs directed to nfP2X7 have the potential to treat many common as well as rare cancers whilst avoiding the toxicity seen with many marketed cancer drugs. We have exploited this unique profile by developing a pipeline of discovery and clinical programmes against cancer.

Biosceptre Pipeline of Therapeutics targeting nfP2X7.

The most advanced of Biosceptre’s development programmes is our peptide vaccine BIL06v, a therapeutic anti-cancer vaccine which is currently recruiting  A Phase 1 trial which includes a number of secondary and exploratory endpoints more typical of a Phase 1b/2a trial.

Biosceptre’s also has a rich suite of antibody candidates in preclinical optimisation and discovery stage including  BIL03s, a human domain antibody for systemic administration to treat a variety of tumours which is approved to enter a Phase I clinical trial.

Biosceptre’s proprietary target nfP2X7 has important potential advantages over current chemotherapy, radiation and other oncology immunotherapies including:

  • Low toxicity: Formal toxicity trials and a successful phase I trial confirm a good safety profile for therapeutics targeting nfP2X7
  • Selectivity: nfP2X7 is expressed on cancer cells and absent from the surface of normal cells
  • Breadth of application across a broad range of cancers: nfP2X7 is broadly expressed on multiple cancers including but not limited to breast, prostate, lung, melanoma and bladder.

Biosceptre is also developing additional therapeutic modalities to target nfP2X7 including CAR-T cell therapies.

In addition, detection of nfP2X7 has potential as a powerful diagnostic approach using our IHC antibody BPM09 (Published paper).